DR-143 Detection of microsatellite instability in metastatic colorectal cancer: the diagnostic accuracy of routine mismatch repair or microsatellite testing compared to whole genome sequencing.
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-143 Detection of microsatellite instability in metastatic colorectal cancer: the diagnostic accuracy of routine mismatch repair or microsatellite testing compared to whole genome sequencing.
The prognosis of patients with metastatic colorectal cancer is poor. Some of these patients are eligible for receiving potentially life-saving …
DR-188 Leveraging tumor evolutionary dynamics for selection inference in human cancers
Cancer is a genetic disease, caused by changes in the cellular hereditary material. When a cancer tumor is detected, a …
DR-187 Discovering non-coding driver alterations and the clinical utility of mutational signatures
Cancers develop by the accumulation of “driver” genetic alterations providing tumor cells a growth advantage. Whole genome sequencing allows to …
DR-184 Combatting therapy resistance in advanced breast cancer
We are investigating drug resistance mechanisms in two different types of breast cancer, 1) invasive lobular carcinoma (ILC) to PI3K/mTOR …
DR-178 Image-driven prognostic chemotherapy response insights using Artificial Intelligence
Modern machine learning techniques will be applied to the data in an exploratory study in order to identify possible new …
DR-176 Responder study, Biomarker discovery study to identify patients with advanced urothelial cancer benefitting from pembrolizumab treatment.
Immune checkpoint inhibitors have been approved for first- and second-line treatment of metastatic urothelial cancer (mUC) patients, and lead to …
DR-174 Effects of FHIT gene in cancers
We aim to understand the effects of the FHIT gene in cancers. FHIT is involved in purine metabolism, and contains …
DR-173 Detection of microsatellite instability in metastatic colorectal cancer: the diagnostic accuracy of routine mismatch repair or microsatellite testing compared to whole genome sequencing.
The prognosis of patients with metastatic colorectal cancer is poor. Some of these patients are eligible for receiving potentially life-saving …
DR-172 Detecting RET gene fusions in lung cancer: multicenter experience and comparison of molecular testing modalities
RET fusion gene testing will soon become very important for selection of lung cancer patients for treatment with the novel …
DR-170 Combining somatic alterations in intergenic, intronic and exonic regions to improve tumor mutational burden estimation by targeted sequencing.
Purpose: To develop an algorithm for robust estimation of the tumor mutational burden (TMB) using targeted sequencing. Data: Somatic analyses …
DR-169 Assessing drug response in breast cancer tissue samples
Breast cancer (BC) is the most common malignancy among women, constituting the prominent cause of cancer-associated mortality. Despite considerable knowledge …
DR-165 Dynamical modelling of somatic genomes: structural variation and tumour evolution
Cancer cells can have very high mutation rates, an effect known as genetic instability. This creates high levels of structural …
Kankers zullen steeds vaker voldoen aan de definitie van ‘zeldzaam’ als het gaat om de moleculaire profielen die elke tumor uniek maakt. Hoe meer onderzoek we hiernaar doen, hoe beter we in de toekomst elke patiënt een op maat gemaakte behandeling kunnen aanbieden. Whole genome sequencing en studies als DRUP leveren hier een belangrijke bijdrage aan.